LOGIN  |  REGISTER
Assertio

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 403.55
9.89 2.51
2.46M
382.50M
US$ 154.360B
US$ 189.18
4.64 2.51
2.78M
722.28M
US$ 136.640B
US$ 516.50
11.67 2.31
599,061
81.88M
US$ 42.290B
US$ 85.33
0.50 0.59
1.97M
390.60M
US$ 33.330B
US$ 111.26
2.73 2.52
1.97M
285.60M
US$ 31.780B
US$ 140.54
3.54 2.58
1.63M
181.50M
US$ 25.510B
US$ 1.00
48.70 4.37
157,186
21.10M
US$ 24.540B
US$ 358.36
11.99 3.46
421,334
59.38M
US$ 21.280B
US$ 157.16
4.68 3.07
1.01M
132.02M
US$ 20.750B
US$ 247.69
5.16 2.13
648,091
83.64M
US$ 20.720B
US$ 173.68
2.45 1.43
1.03M
111.62M
US$ 19.390B
US$ 82.49
1.95 2.42
1.82M
158.60M
US$ 13.080B
US$ 92.23
2.90 3.25
1.52M
121.70M
US$ 11.220B
US$ 131.38
4.39 3.46
1.67M
82.56M
US$ 10.850B
US$ 56.56
0.08 0.14
2.07M
185.08M
US$ 10.470B
US$ 65.87
6.62 11.17
16.46M
152.40M
US$ 10.040B
US$ 43.85
1.80 4.28
1.87M
222.26M
US$ 9.750B
US$ 298.59
5.56 1.90
191,020
31.08M
US$ 9.280B
US$ 138.65
1.92 1.40
765,992
51.14M
US$ 7.090B
US$ 75.76
1.01 1.35
919,766
69.53M
US$ 5.270B
US$ 39.17
2.12 5.72
1.80M
123.56M
US$ 4.840B
US$ 56.68
-0.09 -0.16
447,215
74.03M
US$ 4.200B
US$ 12.43
0.17 1.39
558,259
283.24M
US$ 3.520B
US$ 31.26
1.08 3.58
1.53M
67.26M
US$ 2.100B
US$ 29.41
1.25 4.44
1.05M
59.58M
US$ 1.750B
US$ 6.15
-0.04 -0.65
3.37M
216.94M
US$ 1.330B
US$ 7.50
0.22 3.02
1.10M
128.36M
US$ 962.700M
US$ 17.63
0.52 3.04
1.36M
53.63M
US$ 945.500M
US$ 1.31
0.04 3.15
2.39M
672.80M
US$ 881.370M
US$ 20.19
-0.33 -1.61
337,829
30.59M
US$ 617.610M
US$ 3.77
0.00 0.00
62,855
139.82M
US$ 527.120M
US$ 15.80
-0.09 -0.57
523,100
28.01M
US$ 442.560M
US$ 28.81
-0.35 -1.20
33,601
14.29M
US$ 411.690M
US$ 1.03
0.08 7.91
2.17M
372.26M
US$ 383.430M
US$ 4.15
0.22 5.60
2.27M
91.04M
US$ 377.820M
US$ 13.64
-0.15 -1.09
97,679
23.48M
US$ 320.270M
US$ 0.91
-0.03 -3.35
14.49M
294.32M
US$ 267.830M
US$ 1.91
0.17 9.77
20.33M
138.40M
US$ 264.340M
C$ 0.87
0.03 3.57
217,500
282.82M
C$ 246.050M
US$ 3.97
-0.02 -0.50
688,584
55.65M
US$ 220.930M
US$ 6.81
0.78 12.94
219,741
17.64M
US$ 120.130M
US$ 10.00
1.91 23.61
32,659
10.64M
US$ 106.400M
US$ 2.12
0.06 2.91
46,329
49.50M
US$ 104.940M
US$ 2.55
0.44 20.85
1.69M
32.02M
US$ 81.650M
C$ 0.55
0.00 0.00
66,050
113.40M
C$ 62.370M
US$ 1.68
-0.20 -10.64
493,294
32.80M
US$ 55.100M
US$ 0.35
-0.01 -3.06
3.26M
145.47M
US$ 50.190M
US$ 0.48
-0.03 -6.11
216,458
95.97M
US$ 46.450M
US$ 4.35
2.45 128.95
4,938
10.07M
US$ 43.800M
US$ 1.61
0.03 1.58
75,914
26.67M
US$ 42.940M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.53
-0.02 -4.13
379,211
55.19M
US$ 29.090M
US$ 3.30
0.07 2.17
11,230
8.53M
US$ 28.150M
US$ 0.72
0.00 0.00
74,386
38.39M
US$ 27.560M
C$ 0.30
0.00 0.00
2,000
90.89M
C$ 27.270M
C$ 0.32
-0.005 -1.54
42,252
59.60M
C$ 19.070M
US$ 0.68
-0.07 -8.78
42,867
27.52M
US$ 18.580M
US$ 0.32
0.00 0.00
0
52.24M
US$ 16.610M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 10.04
0.29 2.97
10,458
1.48M
US$ 14.860M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.530M
C$ 0.09
-0.005 -5.56
72,000
100.02M
C$ 8.500M
US$ 0.25
0.0084 3.49
813,744
31.93M
US$ 7.950M
C$ 0.06
0.005 9.09
8,500
101.29M
C$ 6.080M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
US$ 0.83
-0.02 -2.83
11,849
5.85M
US$ 4.840M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 2.09
-0.01 -0.48
95,856
2.22M
US$ 4.640M
US$ 0.27
-0.0033 -1.20
1.27M
15.58M
US$ 4.240M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 0.15
0.04 36.53
5
21.04M
US$ 3.110M
US$ 3.17
0.04 1.28
91,069
536,908
US$ 1.700M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 1.12
-0.02 -1.75
60,771
962,637
US$ 1.080M
US$ 0.03
0.00 0.00
0
25.04M
US$ 851K
US$ 0.00
0.00 0.00
0
6.39M
US$ -

Latest News From Diagnostics & Research Stocks


Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to give clinicians critical insights to guide optimal treatment PALO ALTO, Calif. / May 27, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand... Read more


Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also... Read more


ICON to Present at the William Blair 45th Annual Growth Stock Conference

DUBLIN / May 27, 2025 / Business Wire / ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under “Events”. About ICON... Read more


Agilent Technologies Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

Setting new standards for intelligent mass detection, sensitivity, and sustainability SANTA CLARA, Calif. / May 27, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse... Read more


Tempus AI: New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes ALISO VIEJO, Calif. / May 27, 2025 / Business Wire / Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study reveals the potentially transformative... Read more


BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent

VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO's intention to grant BioNxt its core patent without significant changes. The Company's core patent filing was a comprehensive application... Read more


Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance... Read more


Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis. / May 22, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast... Read more


Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to feature largest study evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection in colon cancer using Guardant Reveal PALO ALTO, Calif. / May 22, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today... Read more


Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30... Read more


QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN’s global reach and automation expertise with ID Solutions’ assay development for research purposes and manufacturing strengths VENLO, Netherlands / May 22, 2025 / Business Wire / QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing... Read more


Inotiv to Present at Jefferies Global Healthcare Conference 2025

WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation... Read more


PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centers MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access... Read more


Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / May 22, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector,... Read more


Tempus AI to Present at the William Blair 45th Annual Growth Stock Conference

CHICAGO / May 21, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company... Read more


Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif. / May 21, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists... Read more


Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light... Read more


Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’... Read more


BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring an artificial intelligence (AI) approach using... Read more


Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers PALO ALTO, Calif. / May 20, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test,... Read more


VolitionRx Announces Successful Detection of Nucleosomes in Cats

Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been... Read more


Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease and therapeutic drug monitoring WALTHAM, Mass. / May 19, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked... Read more


Aspira Women's Health Announces First Quarter 2025 Financial Results and Provides Business Update

AUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team. Key financial highlights for the quarter are summarized... Read more


Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update

Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial 150-page strategic business plan and advanced financial models completed Investor outreach launched to fund clinical execution and market entry Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products... Read more


IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

RESEARCH TRIANGLE PARK, N.C. / May 16, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities... Read more


Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read... Read more


Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested... Read more


Quantum-Si Reports First Quarter 2025 Financial Results

Launches and Delivers First Platinum® Pro Units Announces New Library Preparation Development Program BRANFORD, Conn. / May 15, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2025. Press Release Highlights First quarter 2025 revenue of $842,000, an 84% increase over the first quarter of 202... Read more


Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy

N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a global leader in genomics solutions,... Read more


European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress

Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming EHA 2025 Congress. The new abstract is titled "Advanced Risk... Read more


Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif. / May 15, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can... Read more


Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. The presentation titled “Time to Diagnosis of Lung Cancer from Identification of a... Read more


VolitionRx Announces First Quarter 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss... Read more


Applied DNA Sciences Reports Second Quarter Fiscal 2025 Financial Results

Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues  Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET  STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025... Read more


Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part... Read more


bioAffinity Technologies Reports First Quarter 2025 Results

CyPath® Lung sales up 276% year-over-year SAN ANTONIO / May 15, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025. Key Highlights Generated revenue of $1.9 million in the first quarter of 2025. CyPath® Lung sales up... Read more


ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

ANN ARBOR, Mich. / May 15, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease.... Read more


Sera Prognostics To Present At RBC Global Healthcare Conference

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide... Read more


Bionano Genomics Reports First Quarter 2025 Results and Highlights Recent Business Progress

Conference call today, May 14, 2025, at 4:30 PM ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.  ... Read more


Tempus AI Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

CHICAGO / May 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. Despite... Read more


MDxHealth Reports Q1-2025 Results

Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO... Read more


DarioHealth Reports First Quarter 2025 Financial and Operating Results

First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially. Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024 Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024 Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through... Read more


Precipio Announces its Q1-2025 Financial Results

Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain confident in the Company’s trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing... Read more


Tempus AI Announces Six Posters Accepted for Presentation at ISPOR 2025

CHICAGO / May 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting... Read more


IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

WESTBROOK, Maine / May 13, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation... Read more


StageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer

TORONTO, ON  - TheNewswire - May 13, 2025 - StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), and ElevationMD (“ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer. StageZero is an integrated healthcare company with the first and only... Read more


Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO, May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis... Read more


Neogen Announces Board Transition with Appointment of Andrea Wainer and Retirement of James P. Tobin

LANSING, Mich. / May 13, 2025 / Business Wire / Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that James P. Tobin has chosen to retire from the Company’s Board of Directors, effective May 31, 2025. Mr. Tobin has served on Neogen’s Board since 2016 and currently chairs the Governance and Sustainability Committee and serves on the Audit Committee. James C. Borel, Chair of the Neogen Board of Directors, will serve as... Read more


Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

SAN DIEGO / May 13, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company’s biosensing platforms since the launch of its first commercial system. In his chief operating officer... Read more


HeartBeam Reports First Quarter 2025 Results

Successfully Met Clinical Endpoints in the VALID-ECG Pivotal Study Showing 93.4% Overall Diagnostic Agreement for Assessment of Arrhythmia Productive Discussions with FDA on 510(k) Submission for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Signed Strategic Collaboration with AccurKardia to Enhance Commercial Offering for Arrhythmia Assessment Added Two New US Patents to Robust IP Portfolio and Differentiated Position in Remote Cardiac Diagnosti... Read more